Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

This study (PROMPT-R) uses a PSMA PET scan (a highly sensitive imaging test for prostate cancer) to evaluate how well targeted radiation to a small number of cancer sites (oligometastatic disease) works in men with hormone-sensitive prostate cancer. **You may be eligible if...** - You are 18 or older with good overall health (KPS ≥ 70 or ECOG 0–1) - You have castration-sensitive prostate cancer (responding to hormone levels) - You have 5 or fewer metastatic sites outside the pelvis (not in brain or liver) - Your cancer has been confirmed by biopsy as prostate adenocarcinoma - Your PSA is rising and testosterone is above 100 ng/dL **You may NOT be eligible if...** - You have more than 5 metastatic sites - Your cancer has spread to the brain or liver - Your cancer has become resistant to hormone therapy (castration-resistant) - You do not meet health and performance requirements Talk to your doctor to see if this trial is right for you.